# Corvus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corvus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Burlingame, US
- Website: www.corvuspharma.com
- Total disclosed funding: $109M
- Latest round: Series B (Sep 16, 2015)
- Investors on record: 11

## About

Corvus Pharmaceuticals, Inc., based in the US, specializes in developing innovative therapies for immune diseases and cancer, particularly with its lead product, soquelitinib, which targets immune response modulation.Founded in 2014, Corvus Pharmaceuticals, Inc. operates from Burlingame, California, and focuses on developing advanced therapies for conditions like cancer. The company has raised USD 31.80 mn through various funding rounds, including a Private Placement of USD 29.99 mn in February 2021. The founder, Peter Thompson, has a history in the pharmaceuticals sector, although no other previous companies are noted. The company has participated in 5 deals to date, with its most recent deal occurring on February 12, 2021.Corvus Pharmaceuticals focuses on developing innovative therapies aimed at treating immune diseases and cancer, emphasizing their lead product, soquelitinib. This first-in-class oral therapy selectively inhibits ITK (interleukin-2-inducible T-cell kinase), which plays a critical role in modulating immune responses. By targeting ITK, soquelitinib aims to enhance the effectiveness of immune system signaling pathways, offering potential benefits for patients suffering from various immune-related conditions and specific cancer types. The company primarily serves healthcare professionals, hospitals, and clinics within the oncology and immunology sectors, with a strategic focus on markets in North America, Europe, and parts of Asia.Revenue generation for Corvus Pharmaceuticals is centered around their therapeutic product offerings, particularly soquelitinib. The company engages in business transactions primarily through partnerships with pharmaceutical distributors and healthcare providers. These transactions can involve direct sales agreements, where healthcare institutions procure the drug for patient use, or collaborative arrangements with larger pharmaceutical firms for joint development and commercialization efforts. Pricing structures are designed to reflect the value of the innovative treatment provided, with strategies tailored to accommodate different market conditions and healthcare reimbursement frameworks. The company’s revenue stream is closely tied to the successful development and regulatory approval of its products, which positions Corvus to capitalize on the growing demand for advanced therapies in oncology and immunology.Corvus Pharmaceuticals plans to utilize the funds raised in its recent Private Placement to support the further development of soquelitinib and other pipeline products. The company has not publicly specified upcoming product launches or release dates but is likely to continue its research into new therapies that address unmet medical needs in oncology and immunology. Corvus also aims to explore expansion opportunities into additional markets in Europe and Asia, leveraging its existing partnerships to enhance market presence. The strategic direction includes maintaining a focus on innovation while broadening its therapeutic offerings to address a wider range of conditions by 2023.

## Funding rounds

- Series B, Sep 16, 2015, $75M — Adams Street Partners, OrbiMed Advisors, Novo Holdings, Fidelity Investments, Roche Venture Fund, BlackRock, Sphera Fund Management, Jennison Associates, VenBio, Rock Springs Capital, Cormorant Asset Management
- Series A, Dec 5, 2014, $34M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series B
- Novo Holdings — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Sphera Fund Management — Series B
- Jennison Associates — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B